Zimmer Biomet reports Q1 adjusted EPS $1.89, consensus $1.64

Reports Q1 revenue $1.83B, consensus $1.7B. "Our strong performance in Q1 outpaced our internal growth expectations, driven by continued procedure recovery, solid execution and increasing traction around ZB innovation," said Bryan Hanson, chairman, president and CEO of Zimmer Biomet. "I’m proud of how our team continues to successfully navigate and manage the broader market challenges posed by inflation and the supply chain and how we are driving positive momentum as we deliver on our mission and bring value to our patients, customers and shareholders."